ERBB2 and invasive ductal breast carcinoma: In 2023, Khan et al.38 enrolled 32 patients with a diagnosis of clinically node-negative, ER/PR-positive, HER2-negative infiltrating ductal carcinomas 1.5 cm or smaller and a mean age of 71 years.